登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《NEJM，7月14日，An mRNA Vaccine against SARS-CoV-2 — Preliminary Report》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-07-28

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    List of authors.

    Lisa A. Jackson, M.D., M.P.H., Evan J. Anderson, M.D., Nadine G. Rouphael, M.D., Paul C. Roberts, Ph.D., Mamodikoe Makhene, M.D., M.P.H., Rhea N. Coler, Ph.D., Michele P. McCullough, M.P.H., James D. Chappell, M.D., Ph.D., Mark R. Denison, M.D., Laura J. Stevens, M.S., Andrea J. Pruijssers, Ph.D., Adrian McDermott, Ph.D., et al., for the mRNA-1273 Study Group*

    Abstract

    BACKGROUND

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.

    METHODS

    We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.

  • 原文来源：https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?query=featured_home
113浏览量
原文链接
相关报告

  • 《Immunity，3月7日，SARS-CoV-2 vaccines: status report》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-30
    • SARS-CoV-2 vaccines: status report Fatima Amanat 1,2 and Florian Krammer2 1Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 170,000 individuals and caused more than 6500 deaths globally. Here we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to have an impact on the first wave of a potential pandemic. Nevertheless, important lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
    81浏览量
    原文链接

  • 《Nature，7月30日，Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-08-19
    • Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques Noe B. Mercado, Roland Zahn, […]Dan H. Barouch Nature (2020) Abstract A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
    114浏览量
    原文链接